Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
Provided By GlobeNewswire
Last update: Apr 14, 2025
Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort
Read more at globenewswire.com5.67
+0.21 (+3.85%)
Find more stocks in the Stock Screener
VERV Latest News and Analysis
16 days ago - ChartmillUnusual volume stocks are being observed in Tuesday's session.Let's have a look at what is happening on the US markets on Tuesday. Below you can find the stocks with an unusual volume in today's session.
16 days ago - ChartmillThe market is filled with gapping stocks in Tuesday's session.In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.
17 days ago - ChartmillGapping stocks in Monday's sessionInvestors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
17 days ago - ChartmillThese stocks are moving in today's pre-market sessionThe US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
